Padagis Us
United States Updated 9 July 2026
Padagis Us is a finished-dose manufacturer based in United States. It holds one active US drug master file. Its filings concentrate with US FDA and DMP (NO). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 6 September 2024 as VAI.
1
registered plants
1 with an FDA FEI number
59
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 6 September 2024 VAI US FDA
- 31 January 2024 NAI US FDA
- 5 May 2023 NAI US FDA
- 18 February 2022 VAI US FDA
- 23 October 2019 NAI US FDA
- 7 July 2017 VAI US FDA
- 6 November 2013 NAI US FDA
- 6 February 2013 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Minneapolis, United States | 2127022 |
What they file, and where
| Molecule | Regulators | Docs |
| Conjugated Estrogens | US FDA | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 57 | 1 |
| DMP (NO) | 2 | None |
Comparing suppliers?
Choose your molecules and target markets. Padagis Us comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 16 active litigation matters are on record.
- The most recent inspection outcome was VAI, on 6 September 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates